Acorda Therapeutics, Inc.
THERAPEUTIC DOSING OF A NEUREGULIN OR A FRAGMENT THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE

Abstract:

The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.